Single-dose version of Ilex leukemia drug approved for US market.
In: PharmaWatch: Cancer, Jg. 3 (2004-12-01), Heft 12, S. 19-19
report
Zugriff:
Reports that the U.S. Food and Drug Administration has granted marketing approval to Berlex and Ilex Oncology's leukemia drug Campath in a new single-dose vial. Likelihood of the new formulation to be three times more concentrated that the currently marketed Campath; Convenience of the new concentrated formulation to physicians; Indication of Campath for the treatment of patients with B-cell chronic lymphocytic leukemia who have failed fludarabine therapy.
Titel: |
Single-dose version of Ilex leukemia drug approved for US market.
|
---|---|
Zeitschrift: | PharmaWatch: Cancer, Jg. 3 (2004-12-01), Heft 12, S. 19-19 |
Veröffentlichung: | 2004 |
Medientyp: | report |
Schlagwort: |
|
Sonstiges: |
|